Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Navitor TAVI system receives CE Mark for expanded indication to treat more people with aortic stenosis – Abbott

Written by | 8 Sep 2025

Abbott announced it has received CE Mark in Europe for an expanded indication for the company’s Navitor transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic,… read more.

Prompt intervention for severe aortic stenosis patients demonstrates lower healthcare costs, improved clinical outcomes – Edwards Lifesciences

Written by | 13 Jul 2025

Edwards Lifesciences announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body… read more.

Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients – Medtronic

Written by | 14 Jun 2025

Medtronic plc announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a… read more.

FDA approval for the transcatheter aortic valve replacement therapy, the SAPIEN 3 platform, for severe aortic stenosis patients without symptoms – Edwards Life Sciences

Written by | 25 May 2025

Edwards Lifesciences announced that the(FDA has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the… read more.

Medtronic announces strongly positive results for patients from procedural and design innovation of Evolut TAVR

Written by | 5 Jan 2025

Medtronic plc announced new data for the Evolut Transcatheter Aortic Valve Replacement System (TAVR) at PCR London Valves 2024. This new clinical evidence brings further insights to global… read more.

Edwards Lifesciences announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve

Written by | 4 Dec 2024

Edwards Lifesciences  announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously… read more.

Launch of Sapien 3 Ultra RESILIA valve in Europe with technology to enhance durability – Edwards Lifesciences

Written by | 11 May 2024

Edwards Lifesciences announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed… read more.

AHA 2021: Early heart valve surgery could benefit asymptomatic severe aortic stenosis patients

Written by | 23 Nov 2021

Persons diagnosed with severe aortic stenosis, but without symptoms or need of symptom relief, could benefit from early aortic valve replacement surgery since it reduces the risk of… read more.

Real world study of SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement shows positive outcomes in aortic stenosis – Edwards Lifesciences

Written by | 26 May 2021

Edwards Lifesciences announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.